http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2018124153-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-515 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2017-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2018124153-A1 |
| titleOfInvention | Biomarker, test method and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug |
| abstract | By measuring VEGF-A, VEGF-D, sVEGFR-2, SDF-1α, and cNRP1, it is possible to predict the therapeutic effect and prognosis of anti-VEGFR-2 antibody pharmaceuticals, particularly ramcilmab administration. An anti-VEGFR-2 antibody pharmaceutical, particularly a biomarker for predicting the effect of administration of ramcilmab, a test method using the marker, and a test kit can be provided. [Selection figure] None |
| priorityDate | 2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.